Here’s what you need to know:
1. Cchek is developed by ITUS, a Los Angeles-based biotechnology development and acquisition company. Cchek is a noninvasive blood test, which detects immune system cells associated with tumors.
2. ITUS has successfully used Cchek to detect liver cancer in patients who were previously diagnosed using traditional methods, like surgical biopsies.
3. The company has also seen successful results when using Cchek to detect breast cancer, colorectal cancer, lung cancer, ovarian cancer and melanoma.
More articles on gastroenterology and endoscopy:
What is the future of colorectal cancer screening? Still colonoscopy, says Dr. David A. Johnson
Predictive overbooking maximizes endoscopy clinic scheduling: 5 study insights
GI societies advocate for increased coverage of CRC screening, treatment: 4 notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.